Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVM-200 in advanced NSCLC, ovarian, and prostate cancer
NCT05104515Phase 1Recruiting
- Sponsor
- Oxford Vacmedix
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ovm-200 in non-small cell lung cancer (NSCLC), ovarian cancer and prostate cancer (PCa), sponsored by Oxford Vacmedix. Primary endpoint: Occurrence and intensity of adverse events at 24 Weeks. Started Nov 2021; status: recruiting.
02
Drugs
ovm-200
03
Conditions
non-small cell lung cancer (NSCLC)ovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05104515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104515.